Class / Patent application number | Description | Number of patent applications / Date published |
560169000 | Additional nitrogen in acid moiety | 9 |
20100130770 | N-ALKANOYL-N,N',N'-ALKYLENEDIAMINE TRIALKANOIC ACID ESTERS - A method of preparing a N-acyl-N,N′,N′-alkylenediamine trialkanoic acid ester comprising contacting a cyclic amidine with an ester of a haloalkanoic acid is provided. In some embodiments, the method involves preparing a N-acyl-N,N′,N′-ethylenediamine trialkanoic acid ester by contacting a 2-alkyl imidazoline with the ester of haloalkanoic acid. In some embodiments, the N-acyl-N,N′,N′-alkylenediamine trialkanoic acid ester is a synthetic intermediate in the preparation of a N-acyl-N,N′,N′-alkylenediamine trialkanoic acid or a salt thereof. In some embodiments, the method provides novel N-acyl-N,N′,N′-alkylenediamine trialkanoic acids and/or esters, which can be used, for example, as chelating agents. | 05-27-2010 |
20100152480 | PROCESS FOR SYNTHESIS OF CATIONIC SURFACTANTS - The present invention relates to the methods of synthesizing hydrochloride salt of N-fatty acyl substituted amino acid ethyl ester which comprises a) condensation of aqueous solution of esterified amino acid with an acid halide to obtain an intermediate suspension and b) isolating a hydrochloride salt of N-fatty acylsubstituted amino acid ethyl ester from the intermediate suspension. | 06-17-2010 |
20110077423 | PROCESS FOR THE SYNTHESIS OF HYDROCHLORIDE SALT OF N-FATTY ACYLSUBSTITUTED AMINO ACID ETHYL ESTERS - The present invention relates to a process for preparing hydrochloride salt of N-fatty acyl substituted amino acid ethyl ester. Said process includes the steps of: dissolving L-arginine ethyl ester dihydrochloride in distilled water with continuous agitation for a period of about 10 to about 20 minutes to obtain a clear solution; lowering the temperature of the clear solution to about 5° C. to about 10° C. to obtain a cooled solution; adjusting the pH of the cooled solution in the range of about 7 to about 8 by adding sodium hydroxide solution; adding at least one organic solvent to the clear solution with continuous agitation to obtain an intermediate mixture; condensing the intermediate mixture by simultaneously adding an acid halide and 20% sodium hydroxide solution at a temperature of about 7° C. to about 9° C. and at a pH in the range of about 7.2 to about 7.5 for about 2 hours to obtain a mixture; raising the temperature of the mixture to about 18 to about 20° C. followed by addition of sodium hydroxide to adjust the pH of the mixture to about 7.3; warming the mixture at a temperature of about 25 to about 30° C. to obtain a resultant mixture containing organic phase and aqueous phase; separating the organic phase and aqueous phase of the resultant mixture by settling the mixture; and distilling the organic phase under vacuum at a temperature of about 70° C. to about 75° C. to obtain a hydrochloride salt of ethyl lauroyl arginate. | 03-31-2011 |
20110166379 | Method of synthesis and purification of N-6-Trimethyl-L-Lysine and derivative compounds - The invention provides a method of synthesis of N-6-trimethyl-L-lysine (TML) derivative compounds for potential treatment of disorders resulting from deficiencies in the TML-carnitine pathway. The invention also provides a method of purification of TML and TML derivative compounds. The treatment of conditions of the diseases late infantile neuronal ceroid lipofuscinosis (LINCL) and neuronal ceroid lipofuscinosis (NCL) with TML were shown in the original parent application. | 07-07-2011 |
20110166380 | Derivative compounds of N-6-Trimethy-L-Lysine for therapeutic use - The invention provides derivative compounds of N-6-trimethyl-L-lysine (TML) for potential treatment of disorders resulting from deficiencies in the TML-carnitine pathway. The invention also provides a method of purification of TML and TML derivative compounds. The treatment of conditions of the diseases late infantile neuronal ceroid lipofuscinosis (LINCL) and neuronal ceroid lipofuscinosis (NCL) with TML were shown in the original parent application. | 07-07-2011 |
20110269986 | AMIDES OF CREATNE, METHOD OF THEIR PREPARATION, AND REMEDY POSSESSING A NEUROPROTECTIVE ACTIVITY - The invention relates to pharmaceutical chemistry notably to new biologically active substances (BAS) and their properties. In particular, the invention relates to Creatine derivatives having a general formula: NH═C(NH | 11-03-2011 |
20120203027 | PROCESS FOR PREPARATION OF DIETHYLENETRIAMINEPENTAACETIC ACID DERIVATIVE, AND DIETHYLENETRIAMINEPENTAACETIC ACID DERIVATIVE - The objective of the present invention is to provide a process for simple and efficient preparation of an intermediate compound to synthesize a gadolinium complex having a substituent for improving a retention property in blood time and specificity to an intended organ. The objective of the present invention is also to provide an intermediate compound produced by the said production process. The process for preparation of the diethylenetriaminepentaacetic acid derivative (I): | 08-09-2012 |
20140364642 | COMPOUND HAVING READ-THROUGH ACTIVITY - [Problem] Provision of a novel compound having read-through activity and a drug for the treatment of nonsense mutation-type disease containing this compound. | 12-11-2014 |
20150376116 | VINYL MONOMERS HAVING CHELATING FUNCTIONALITY - The present invention provides novel polymerizable monomers having chelating functionality and processes to make them. In particular, the novel monomers are ethylenically unsaturated aminocarboxylates and are prepared by reacting ethylenediamine triacetic acid or its salt with an ethylenically unsaturated monomer. The ethyleneically unsaturated monomer may be a polymerizable vinyl monomer selected from (o-, p-, m-)DVBMO, allyl glycidyl ether, and glycidyl (meth)acrylate. | 12-31-2015 |